

# Rupert Bartsch

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/4494923/publications.pdf>

Version: 2024-02-01

166  
papers

3,834  
citations

159525

30  
h-index

149623

56  
g-index

167  
all docs

167  
docs citations

167  
times ranked

5395  
citing authors

#	ARTICLE	IF	CITATIONS
1	Pembrolizumab plus trastuzumab in trastuzumab-resistant, advanced, HER2-positive breast cancer (PANACEA): a single-arm, multicentre, phase 1bâ€“2 trial. <i>Lancet Oncology</i> , The, 2019, 20, 371-382.	5.1	327
2	Zoledronic acid combined with adjuvant endocrine therapy of tamoxifen versus anastrozol plus ovarian function suppression in premenopausal early breast cancer: final analysis of the Austrian Breast and Colorectal Cancer Study Group Trial 12. <i>Annals of Oncology</i> , 2015, 26, 313-320.	0.6	251
3	Density of tumor-infiltrating lymphocytes correlates with extent of brain edema and overall survival time in patients with brain metastases. <i>Oncolmunology</i> , 2016, 5, e1057388.	2.1	239
4	Descriptive statistical analysis of a real life cohort of 2419 patients with brain metastases of solid cancers. <i>ESMO Open</i> , 2016, 1, e000024.	2.0	152
5	Capecitabine and Trastuzumab in Heavily Pretreated Metastatic Breast Cancer. <i>Journal of Clinical Oncology</i> , 2007, 25, 3853-3858.	0.8	144
6	Impact of Breast Surgery in Primary Metastasized Breast Cancer. <i>Annals of Surgery</i> , 2019, 269, 1163-1169.	2.1	130
7	Trastuzumab prolongs overall survival in patients with brain metastases from Her2 positive breast cancer. <i>Journal of Neuro-Oncology</i> , 2007, 85, 311-317.	1.4	127
8	Tumor infiltrating lymphocytes and PD-L1 expression in brain metastases of small cell lung cancer (SCLC). <i>Journal of Neuro-Oncology</i> , 2016, 130, 19-29.	1.4	107
9	Activity of T-DM1 in Her2-positive breast cancer brain metastases. <i>Clinical and Experimental Metastasis</i> , 2015, 32, 729-737.	1.7	103
10	Improved Differentiation of Benign and Malignant Breast Tumors with Multiparametric 18Fluorodeoxyglucose Positron Emission Tomography Magnetic Resonance Imaging: A Feasibility Study. <i>Clinical Cancer Research</i> , 2014, 20, 3540-3549.	3.2	82
11	Duration of Adjuvant Aromatase-Inhibitor Therapy in Postmenopausal Breast Cancer. <i>New England Journal of Medicine</i> , 2021, 385, 395-405.	13.9	82
12	Survival prediction using temporal muscle thickness measurements on cranial magnetic resonance images in patients with newly diagnosed brain metastases. <i>European Radiology</i> , 2017, 27, 3167-3173.	2.3	80
13	Brain metastases free survival differs between breast cancer subtypes. <i>British Journal of Cancer</i> , 2012, 106, 440-446.	2.9	74
14	Impact of anti-HER2 therapy on overall survival in HER2-overexpressing breast cancer patients with brain metastases. <i>British Journal of Cancer</i> , 2012, 106, 25-31.	2.9	68
15	The genomic expression test EndoPredict is a prognostic tool for identifying risk of local recurrence in postmenopausal endocrine receptor-positive, her2neu-negative breast cancer patients randomised within the prospective ABCSG 8 trial. <i>British Journal of Cancer</i> , 2015, 112, 1405-1410.	2.9	68
16	Epirubicin and docetaxel with or without capecitabine as neoadjuvant treatment for early breast cancer: final results of a randomized phase III study (ABCSG-24). <i>Annals of Oncology</i> , 2014, 25, 366-371.	0.6	62
17	Breast cancer brain metastases responding to primary systemic therapy with T-DM1. <i>Journal of Neuro-Oncology</i> , 2014, 116, 205-206.	1.4	61
18	Investigating the prediction value of multiparametric magnetic resonance imaging at 3ÂˆT in response to neoadjuvant chemotherapy in breast cancer. <i>European Radiology</i> , 2017, 27, 1901-1911.	2.3	59

#	ARTICLE	IF	CITATIONS
19	Co-overexpression of HER2/HER3 is a predictor of impaired survival in breast cancer patients. <i>Breast</i> , 2014, 23, 637-643.	0.9	56
20	Analysis of trastuzumab and chemotherapy in advanced breast cancer after the failure of at least one earlier combination: An observational study. <i>BMC Cancer</i> , 2006, 6, 63.	1.1	49
21	Ovarian function suppression and fulvestrant as endocrine therapy in premenopausal women with metastatic breast cancer. <i>European Journal of Cancer</i> , 2012, 48, 1932-1938.	1.3	47
22	Diffusion-weighted MRI of breast lesions: a prospective clinical investigation of the quantitative imaging biomarker characteristics of reproducibility, repeatability, and diagnostic accuracy. <i>NMR in Biomedicine</i> , 2016, 29, 1445-1453.	1.6	46
23	Trastuzumab and gemcitabine as salvage therapy in heavily pre-treated patients with metastatic breast cancer. <i>Cancer Chemotherapy and Pharmacology</i> , 2008, 62, 903-910.	1.1	42
24	Fulvestrant (â€Faslodexâ€™™) in pre-treated patients with advanced breast cancer: A single-centre experience. <i>European Journal of Cancer</i> , 2005, 41, 2655-2661.	1.3	39
25	Intensified local treatment and systemic therapy significantly increase survival in patients with brain metastases from advanced breast cancer â€“ A retrospective analysis. <i>Radiotherapy and Oncology</i> , 2006, 80, 313-317.	0.3	39
26	Intrathecal administration of anti-HER2 treatment for the treatment of meningeal carcinomatosis in breast cancer: A metanalysis with meta-regression. <i>Cancer Treatment Reviews</i> , 2020, 88, 102046.	3.4	39
27	Expected Medium- and Long-Term Impact of the COVID-19 Outbreak in Oncology. <i>JCO Global Oncology</i> , 2021, 7, 162-172.	0.8	38
28	CDK4/6 inhibitors in the treatment of patients with breast cancer: summary of a multidisciplinary round-table discussion. <i>ESMO Open</i> , 2018, 3, e000368.	2.0	35
29	Prognostic value of <scp>HMGB</scp> 1 in early breast cancer patients under neoadjuvant chemotherapy. <i>Cancer Medicine</i> , 2016, 5, 2350-2358.	1.3	34
30	Continued Endocrine Therapy Is Associated with Improved Survival in Patients with Breast Cancer Brain Metastases. <i>Clinical Cancer Research</i> , 2019, 25, 2737-2744.	3.2	34
31	Trastuzumab in the management of early and advanced stage breast cancer. <i>Biologics: Targets and Therapy</i> , 2007, 1, 19-31.	3.0	33
32	HER-2-Positive Breast Cancer. <i>BioDrugs</i> , 2007, 21, 69-77.	2.2	30
33	Results from an observational trial with oral vinorelbine and trastuzumab in advanced breast cancer. <i>Breast Cancer Research and Treatment</i> , 2007, 102, 375-381.	1.1	29
34	Pathological Complete Response to Neoadjuvant Trastuzumab Is Dependent on HER2/CEP17 Ratio in HER2-Amplified Early Breast Cancer. <i>Clinical Cancer Research</i> , 2017, 23, 3676-3683.	3.2	29
35	Oncological care organisation during COVID-19 outbreak. <i>ESMO Open</i> , 2020, 5, e000853.	2.0	29
36	Adverse Events of Trastuzumab Emtansine (T-DM1) in the Treatment of HER2-Positive Breast Cancer Patients. <i>Breast Care</i> , 2017, 12, 401-408.	0.8	28

#	ARTICLE	IF	CITATIONS
37	Optimal Management of Brain Metastases from Breast Cancer. <i>CNS Drugs</i> , 2013, 27, 121-134.	2.7	27
38	Port-a-Cath® extravasation of vesicant cytotoxics: Surgical options for a rare complication of cancer chemotherapy. <i>European Journal of Surgical Oncology</i> , 2015, 41, 378-385.	0.5	27
39	Triple-negative breast cancer. <i>Wiener Medizinische Wochenschrift</i> , 2010, 160, 174-181.	0.5	26
40	Discrepancies between ESMO and NCCN breast cancer guidelines: An Appraisal. <i>Breast</i> , 2015, 24, 513-523.	0.9	26
41	Combining standard clinical blood values for improving survival prediction in patients with newly diagnosed brain metastases: development and validation of the LabBM score. <i>Neuro-Oncology</i> , 2017, 19, now290.	0.6	26
42	Alleviation of Brain Edema and Restoration of Functional Independence by Bevacizumab in Brain-Metastatic Breast Cancer: A Case Report. <i>Breast Care</i> , 2014, 9, 134-134.	0.8	25
43	Decreased body mass index is associated with impaired survival in lung cancer patients with brain metastases: A retrospective analysis of 624 patients. <i>European Journal of Cancer Care</i> , 2017, 26, e12707.	0.7	25
44	Oral vinorelbine alone or in combination with trastuzumab in advanced breast cancer: results from a pilot trial. <i>Cancer Chemotherapy and Pharmacology</i> , 2006, 57, 554-558.	1.1	24
45	Efficacy and safety of the therapeutic cancer vaccine tecemotide (L-BLP25) in early breast cancer: Results from a prospective, randomised, neoadjuvant phase II study (ABCSCG 34). <i>European Journal of Cancer</i> , 2020, 132, 43-52.	1.3	24
46	Outcome of chemotherapy extravasation in a large patient series using a standardised management protocol. <i>Supportive Care in Cancer</i> , 2015, 23, 1741-1748.	1.0	23
47	Predicting for activity of second-line trastuzumab-based therapy in her2-positive advanced breast cancer. <i>BMC Cancer</i> , 2009, 9, 367.	1.1	22
48	Single-agent pegylated liposomal doxorubicin (PLD) in the treatment of metastatic breast cancer: results of an Austrian observational trial. <i>BMC Cancer</i> , 2011, 11, 373.	1.1	22
49	BRCA-1 methylation and TP53 mutation in triple-negative breast cancer patients without pathological complete response to taxane-based neoadjuvant chemotherapy. <i>Cancer Chemotherapy and Pharmacology</i> , 2014, 73, 771-778.	1.1	22
50	Prognostic impact of breast cancer subtypes in elderly patients. <i>Breast Cancer Research and Treatment</i> , 2016, 157, 91-99.	1.1	22
51	Prognostic value of monitoring tumour markers CA 15-3 and CEA during fulvestrant treatment. <i>BMC Cancer</i> , 2006, 6, 81.	1.1	21
52	Brain metastases as first manifestation of advanced cancer: exploratory analysis of 459 patients at a tertiary care center. <i>Clinical and Experimental Metastasis</i> , 2018, 35, 727-738.	1.7	21
53	Her2 and Progesterone Receptor Status Are Not Predictive of Response to Fulvestrant Treatment. <i>Clinical Cancer Research</i> , 2007, 13, 4435-4439.	3.2	20
54	PAM-50 predicts local recurrence after breast cancer surgery in postmenopausal patients with ER+/HER2- disease: results from 1204 patients in the randomized ABCSCG-8 trial. <i>British Journal of Surgery</i> , 2021, 108, 308-314.	0.1	19

#	ARTICLE	IF	CITATIONS
55	ASCO 2018: highlights in HER2-positive metastatic breast cancer. Memo - Magazine of European Medical Oncology, 2018, 11, 280-283.	0.3	18
56	Current concepts and future directions in neoadjuvant chemotherapy of breast cancer. Memo - Magazine of European Medical Oncology, 2018, 11, 199-203.	0.3	18
57	Trastuzumab-deruxtecan: an investigational agent for the treatment of HER2-positive breast cancer. Expert Opinion on Investigational Drugs, 2020, 29, 901-910.	1.9	18
58	Impact of Her-2-Targeted Therapy on Overall Survival in Patients With Her-2 Positive Metastatic Breast Cancer. Breast Journal, 2013, 19, 149-155.	0.4	17
59	The European Society for Medical Oncology Magnitude of Clinical Benefit Scale in daily practice: a single institution, real-life experience at the Medical University of Vienna. ESMO Open, 2016, 1, e000066.	2.0	17
60	Persistence of ctDNA in Patients with Breast Cancer During Neoadjuvant Treatment Is a Significant Predictor of Poor Tumor Response. Clinical Cancer Research, 2022, 28, 697-707.	3.2	17
61	Clinicopathologic and Genomic Landscape of Breast Carcinoma Brain Metastases. Oncologist, 2021, 26, 835-844.	1.9	16
62	Extravasation emergencies: state-of-the-art management and progress in clinical research. Memo - Magazine of European Medical Oncology, 2016, 9, 226-230.	0.3	15
63	Palbociclib for the treatment of postmenopausal breast cancer – an update. Expert Opinion on Pharmacotherapy, 2016, 17, 255-263.	0.9	15
64	Sensitive and robust liquid biopsy-based detection of PIK3CA mutations in hormone-receptor-positive metastatic breast cancer patients. British Journal of Cancer, 2022, 126, 456-463.	2.9	15
65	The impact of COVID-19 on cancer care of outpatients with low socioeconomic status. International Journal of Cancer, 2022, 151, 77-82.	2.3	15
66	Retrospective analysis of re-irradiation in malignant glioma: a single-center experience. Wiener Klinische Wochenschrift, 2005, 117, 821-826.	1.0	13
67	ASCO 2017: highlights in breast cancer. Memo - Magazine of European Medical Oncology, 2017, 10, 228-232.	0.3	13
68	A Cross-Sectional Study of Patients' Satisfaction With Totally Implanted Access Ports. Clinical Journal of Oncology Nursing, 2016, 20, 175-180.	0.3	12
69	Ixazomib in combination with carboplatin in pretreated women with advanced triple-negative breast cancer, a phase I/II trial of the AGMT (AGMT MBC-10 trial). BMC Cancer, 2018, 18, 1074.	1.1	12
70	Efficacy and safety of everolimus plus exemestane in patients with HR+, HER2+ advanced breast cancer progressing on/after prior endocrine therapy in routine clinical practice: Primary results from the non-interventional study, STEPAUT. Breast, 2020, 50, 64-70.	0.9	12
71	Anthracyclines Strike Back: Rediscovering Non-Pegylated Liposomal Doxorubicin in Current Therapeutic Scenarios of Breast Cancer. Cancers, 2021, 13, 4421.	1.7	12
72	I-SPY 2: optimising cancer drug development in the 21st century. ESMO Open, 2016, 1, e000113.	2.0	11

#	ARTICLE	IF	CITATIONS
73	Hypothyroidism correlates with favourable survival prognosis in patients with brain metastatic cancer. <i>European Journal of Cancer</i> , 2020, 135, 150-158.	1.3	10
74	The Austrian fulvestrant registry: results from a prospective observation of fulvestrant in postmenopausal patients with metastatic breast cancer. <i>Breast Cancer Research and Treatment</i> , 2009, 115, 373-380.	1.1	9
75	Favourable outcome of patients with breast cancer brain metastases treated with dual HER2 blockade of trastuzumab and pertuzumab. <i>Therapeutic Advances in Medical Oncology</i> , 2021, 13, 175883592110090.	1.4	9
76	ESMO 2020: highlights in breast cancer. <i>Memo - Magazine of European Medical Oncology</i> , 2021, 14, 184-187.	0.3	9
77	SABCS 2020: update on triple-negative and metastatic HER2-positive breast cancer. <i>Memo - Magazine of European Medical Oncology</i> , 2021, 14, 247-251.	0.3	9
78	Indocyanine Green Video Angiography Predicts Outcome of Extravasation Injuries. <i>PLoS ONE</i> , 2014, 9, e103649.	1.1	9
79	Taxanes Plus Trastuzumab Compared To Oral Vinorelbine Plus Trastuzumab in HER2-Overexpressing Metastatic Breast Cancer. <i>Breast Care</i> , 2014, 9, 6-6.	0.8	8
80	ASCO 2020: highlights in breast cancer. <i>Memo - Magazine of European Medical Oncology</i> , 2021, 14, 58-61.	0.3	8
81	Serum interleukin-6 levels in patients with gastric MALT lymphoma compared to gastric and pancreatic cancer. <i>Anticancer Research</i> , 2006, 26, 3187-90.	0.5	8
82	Role of denosumab in breast cancer. <i>Expert Opinion on Biological Therapy</i> , 2009, 9, 1225-1233.	1.4	7
83	Influence of the American ODAC Statement on Austrian Bevacizumab Prescribing Practice for Metastatic Breast Cancer. <i>Oncologist</i> , 2012, 17, e13-e17.	1.9	7
84	The PI3K/AKT/MTOR Signaling Pathway: The Role of PI3K and AKT Inhibitors in Breast Cancer. <i>Current Breast Cancer Reports</i> , 2014, 6, 59-70.	0.5	7
85	CDK4/6 inhibitors in luminal breast cancer. <i>Lancet Oncology</i> , The, 2015, 16, 2-3.	5.1	7
86	Targeted Therapy Recommendations for Therapy Refractory Solid Tumors – Data from the Real-World Precision Medicine Platform MONDTI. <i>Journal of Personalized Medicine</i> , 2020, 10, 188.	1.1	7
87	Optimal Strategies for Successful Initiation of Neratinib in Patients with HER2-Positive Breast Cancer. <i>Clinical Breast Cancer</i> , 2021, 21, e575-e583.	1.1	7
88	Impact of COVID-19 lockdown on routine oncology versus emergency care at a high volume cancer centre. <i>European Journal of Clinical Investigation</i> , 2021, 51, e13623.	1.7	7
89	The cancer survival index – A prognostic score integrating psychosocial and biological factors in patients diagnosed with cancer or haematologic malignancies. <i>Cancer Medicine</i> , 2022, 11, 3387-3396.	1.3	7
90	Cardio-oncology in Austria: cardiotoxicity and surveillance of anti-cancer therapies. <i>Wiener Klinische Wochenschrift</i> , 2022, 134, 654-674.	1.0	7

#	ARTICLE	IF	CITATIONS
91	Breast cancer brain metastases responding to lapatinib plus capecitabine as second-line primary systemic therapy. <i>Anti-Cancer Drugs</i> , 2015, 26, 579-581.	0.7	6
92	Ovarian Function Suppression: A Deeper Consideration of the Role in Early Breast Cancer and its Potential Impact on Patient Outcomes: A Consensus Statement from an International Expert Panel. <i>Oncologist</i> , 2022, 27, 722-731.	1.9	6
93	Darbepoetin ?? as treatment for anemia in patients receiving chemotherapy: a single-center experience. <i>Anti-Cancer Drugs</i> , 2005, 16, 617-620.	0.7	5
94	Factors influencing agreement of breast cancer luminal molecular subtype by Ki67 labeling index between core needle biopsy and surgical resection specimens. <i>Virchows Archiv Fur Pathologische Anatomie Und Physiologie Und Fur Klinische Medizin</i> , 2020, 477, 545-555.	1.4	5
95	The Role of Supportive Therapy in the Era of Modern Adjuvant Treatment &ndash; Current and Future Tools. <i>Breast Care</i> , 2009, 4, 167-176.	0.8	4
96	Trends and Novel Approaches in Neoadjuvant Treatment of Breast Cancer. <i>Breast Care</i> , 2011, 6, 427-433.	0.8	4
97	Postoperative CMF Does Not Ameliorate Poor Outcomes in Women With Residual Invasive Breast Cancer After Neoadjuvant Epirubicin/Docetaxel Chemotherapy. <i>Clinical Breast Cancer</i> , 2015, 15, 505-511.	1.1	4
98	ASCO 2016: highlights in breast cancer. <i>Memo - Magazine of European Medical Oncology</i> , 2016, 9, 211-214.	0.3	4
99	Expectations and perception of cancer treatment goals in previously untreated patients. The EXPECT trial. <i>Supportive Care in Cancer</i> , 2021, 29, 3585-3592.	1.0	4
100	Thirteen-year analyses of medical oncology outpatient day clinic data: a changing field. <i>ESMO Open</i> , 2020, 5, e000880.	2.0	4
101	The iTOP trial: Comparing immediate techniques of oncoplastic surgery with conventional breast surgery in women with breast cancer - A prospective, controlled, single-center study. <i>International Journal of Surgery</i> , 2022, 104, 106694.	1.1	4
102	Bevacizumab: no comeback in early breast cancer?. <i>Lancet Oncology</i> , The, 2015, 16, 1001-1003.	5.1	3
103	Pathological complete remission and long-term outcomeâ€”what do we know in 2016?. <i>Lancet Oncology</i> , The, 2016, 17, 693-694.	5.1	3
104	Ribociclib: a valuable addition to treatment options in breast cancer?. <i>ESMO Open</i> , 2017, 2, e000246.	2.0	3
105	SABCS 2017: update on chemotherapy, targeted therapy, and immunotherapy. <i>Memo - Magazine of European Medical Oncology</i> , 2018, 11, 204-207.	0.3	3
106	Conventional versus reverse sequence of neoadjuvant epirubicin/cyclophosphamide and docetaxel: sequencing results from ABCSG-34. <i>British Journal of Cancer</i> , 2021, 124, 1795-1802.	2.9	3
107	Abstract P3-11-06: Bevacizumab in combination with docetaxel+trastuzumab +/- non-pegylated liposomal doxorubicin: Final results of ABCSG-32, a prospective, randomized phase II-study. , 2015, , .		3
108	Plasma PD-L1 concentration in patients with brain metastases from solid tumors.. <i>Journal of Clinical Oncology</i> , 2015, 33, e13026-e13026.	0.8	3

#	ARTICLE	IF	CITATIONS
109	Assessment of the management of carcinomatous meningitis from breast cancer globally: a study by the Breast International Group Brain Metastasis Task Force. <i>ESMO Open</i> , 2022, 7, 100483.	2.0	3
110	Expression of thymidine phosphorylase in peripheral blood cells of breast cancer patients is not increased by paclitaxel. <i>BMC Clinical Pharmacology</i> , 2007, 7, 7.	2.5	2
111	Adjuvant chemotherapy in breast cancer. <i>Memo - Magazine of European Medical Oncology</i> , 2008, 1, 91-98.	0.3	2
112	Axillary Dissection in the Case of Positive Sentinel Lymph Nodes: Results of the Innsbruck Consensus Conference. <i>Geburtshilfe Und Frauenheilkunde</i> , 2012, 72, 293-298.	0.8	2
113	HER2-positive breast cancer: a new piece of the puzzle. <i>Lancet Oncology</i> , The, 2014, 15, 668-669.	5.1	2
114	Highlights from the 2017 St. Gallen Breast Cancer Consensus. <i>Memo - Magazine of European Medical Oncology</i> , 2017, 10, 173-174.	0.3	2
115	Circumnavigating the challenges of COVID-19 in oncology. <i>Memo - Magazine of European Medical Oncology</i> , 2020, 13, 135-138.	0.3	2
116	The Place of Chemotherapy in The Evolving Treatment Landscape for Patients With HR-positive/HER2-negative MBC. <i>Clinical Breast Cancer</i> , 2022, 22, 223-234.	1.1	2
117	Effect of concomitant statin treatment in postmenopausal patients with hormone receptor-positive early-stage breast cancer receiving adjuvant denosumab or placebo: a post hoc analysis of ABCSG-18. <i>ESMO Open</i> , 2022, 7, 100426.	2.0	2
118	Primary systemic treatment of breast-cancer brain metastases. <i>Lancet Oncology</i> , The, 2013, 14, 8-9.	5.1	1
119	Recent developments and translational aspects in targeted therapy for metastatic breast cancer. <i>ESMO Open</i> , 2016, 1, e000036.	2.0	1
120	Rationale of an economically driven PD1 biomarker development in lung cancer – an academic dilemma. <i>Memo - Magazine of European Medical Oncology</i> , 2016, 9, 109-110.	0.3	1
121	Biosimilars in the Treatment of Breast Cancer. <i>Breast Care</i> , 2017, 12, 192-194.	0.8	1
122	ASCO 2019: highlights in HER2-positive metastatic breast cancer. <i>Memo - Magazine of European Medical Oncology</i> , 2019, 12, 308-311.	0.3	1
123	Luminal Metastatic Breast Cancer. <i>Breast Care</i> , 2019, 14, 99-101.	0.8	1
124	An update from the 2019 ASCO Annual Meeting. <i>Memo - Magazine of European Medical Oncology</i> , 2019, 12, 285-285.	0.3	1
125	Position statement of the Austrian Society for Hematology and Medical Oncology on the use of molecular diagnostics in solid tumors. <i>Memo - Magazine of European Medical Oncology</i> , 2020, 13, 450-452.	0.3	1
126	ESMO 2019: breast cancer. <i>Memo - Magazine of European Medical Oncology</i> , 2020, 13, 147-149.	0.3	1



#	ARTICLE	IF	CITATIONS
127	Association of <i>TP53</i> codon 72 polymorphism with <i>TP53</i> mutation in triple-negative breast cancer (TNBC) patients.. Journal of Clinical Oncology, 2014, 32, 1130-1130.	0.8	1
128	Association of tumor-infiltrating lymphocytes with brain edema and overall survival in brain metastases.. Journal of Clinical Oncology, 2014, 32, 2012-2012.	0.8	1
129	A cross-section study evaluating patients'™ satisfaction with totally implanted access ports (PAC) assessing the PAC-related complication rate at two tertiary care centres in Austria.. Journal of Clinical Oncology, 2014, 32, e17574-e17574.	0.8	1
130	PD-L1 expression and tumor infiltrating lymphocytes (TIL) in brain metastases (BM) of small cell lung cancer (SCLC).. Journal of Clinical Oncology, 2016, 34, 8563-8563.	0.8	1
131	Primary tumor sidedness associates with prognosis of patients with brain metastases of colorectal cancer.. Journal of Clinical Oncology, 2017, 35, 3562-3562.	0.8	1
132	Predicting response to second-line trastuzumab-based therapy in patients (pts) with HER2-positive advanced breast cancer (ABC). Journal of Clinical Oncology, 2009, 27, 1090-1090.	0.8	1
133	Position Paper on the Value of Extended Adjuvant Therapy with Neratinib for Early HER2+/HR+ Breast Cancer. Breast Care, 2021, 16, 664-676.	0.8	1
134	Updated Austrian treatment algorithm in HER2+ metastatic breast cancer. Wiener Klinische Wochenschrift, 2022, 134, 63-72.	1.0	1
135	What's™ new in metastatic breast cancer?. Memo - Magazine of European Medical Oncology, 2012, 5, 110-115.	0.3	0
136	ASCO 2013: news in early-stage and advanced breast cancer. Memo - Magazine of European Medical Oncology, 2013, 6, 227-232.	0.3	0
137	Antiangiogenic treatment approaches in breast cancer. Breast Cancer Management, 2013, 2, 397-406.	0.2	0
138	ASCO 2014: highlights in breast cancer. Memo - Magazine of European Medical Oncology, 2014, 7, 242-245.	0.3	0
139	ASCO 2015: Highlights in breast cancer. Memo - Magazine of European Medical Oncology, 2015, 8, 209-212.	0.3	0
140	A welcome statement from the associate Editor-in-Chief. Memo - Magazine of European Medical Oncology, 2016, 9, 106-106.	0.3	0
141	Association of TP53 mutations with TP53 codon 72 polymorphism and outcome in triple-negative breast cancer. Memo - Magazine of European Medical Oncology, 2016, 9, 70-75.	0.3	0
142	My personal highlights of ESMO 2016. Memo - Magazine of European Medical Oncology, 2017, 10, 46-47.	0.3	0
143	To print or not to print. Memo - Magazine of European Medical Oncology, 2017, 10, 1-2.	0.3	0
144	My burning issues in the neoadjuvant treatment for breast cancer. Memo - Magazine of European Medical Oncology, 2018, 11, 27-30.	0.3	0

#	ARTICLE	IF	CITATIONS
145	ESMO 2017â€™my personal highlights. Memo - Magazine of European Medical Oncology, 2018, 11, 77-79.	0.3	0
146	An update on immunotherapy in breast cancer. Memo - Magazine of European Medical Oncology, 2019, 12, 63-66.	0.3	0
147	Optimizing care for geriatric cancer patients: the greatest challenge in medical oncology?. Memo - Magazine of European Medical Oncology, 2019, 12, 288-289.	0.3	0
148	ASCO 2020. Breast Care, 2020, 15, 433-436.	0.8	0
149	Results from the FeDeriCa trial: are we reducing the burden of breast cancer treatment?. Lancet Oncology, The, 2021, 22, 5-6.	5.1	0
150	European Society for Medical Oncology 2020. Memo - Magazine of European Medical Oncology, 2021, 14, 130-131.	0.3	0
151	Intensified local treatment and systemic therapy significantly increase time to progression and survival in patients with brain metastases from advanced breast cancer. Journal of Clinical Oncology, 2006, 24, 10536-10536.	0.8	0
152	Trastuzumab (T) plus capecitabine (C) in heavily pretreated patients (pts) with advanced breast cancer (ABC). Journal of Clinical Oncology, 2007, 25, 1055-1055.	0.8	0
153	Locally advanced gastric cancer treated with neoadjuvant chemotherapy: Epirubicin, oxaliplatin, and capecitabine (EOX).. Journal of Clinical Oncology, 2011, 29, 136-136.	0.8	0
154	Correlation of large brain edema with favorable prognosis in patients with single brain metastases.. Journal of Clinical Oncology, 2012, 30, 2053-2053.	0.8	0
155	Molecular subtyping of breast cancer using dedicated breast PET-CT.. Journal of Clinical Oncology, 2013, 31, e22090-e22090.	0.8	0
156	Effect of multiparametric MRI of the breast on diagnostic accuracy.. Journal of Clinical Oncology, 2014, 32, 11009-11009.	0.8	0
157	Phase II study on the efficacy and safety of lapatinib administered beyond disease progression and combined with vinorelbine in HER-2/neu: Positive advanced breast cancer (CECOG LaVie Trial).. Journal of Clinical Oncology, 2015, 33, e11603-e11603.	0.8	0
158	Effect of laboratory parameters on prognostic value in patients with newly diagnosed brain metastases: Analysis of 1,207 cases.. Journal of Clinical Oncology, 2015, 33, e13034-e13034.	0.8	0
159	Prognostic impact of breast cancer (BC) subtype in elderly patients.. Journal of Clinical Oncology, 2015, 33, e20536-e20536.	0.8	0
160	Current Treatment Strategies in Breast Cancer Brain Metastases. , 2020, , 267-279.		0
161	Expert Discussion: SABCS 2021. Breast Care, 2022, 17, 101-106.	0.8	0
162	Abstract P1-02-07: Accuracy and predictive value of resection margin assessment by intraoperative frozen section after neoadjuvant therapy: An analysis of the ABCSG 24 and 34 trials. Cancer Research, 2022, 82, P1-02-07-P1-02-07.	0.4	0

#	ARTICLE	IF	CITATIONS
163	Abstract P1-02-06: Prediction of Prosigna® breast cancer intrinsic subtype by immunohistochemical ER, PR and Ki67 expression. Cancer Research, 2022, 82, P1-02-06-P1-02-06.	0.4	0
164	Abstract P2-13-30: First interim analysis from ELEANOR: A multi-national, prospective, non-interventional study (NIS) in patients with human epidermal growth factor receptor positive (HER2+) early breast cancer observing real-life extended adjuvant treatment with neratinib. Cancer Research, 2022, 82, P2-13-30-P2-13-30.	0.4	0
165	Abstract P5-07-04: Comprehensive analysis of the gene rearrangements within 822 breast cancer brain metastases reveals an enrichment of cyclin dependent kinase 12 rearrangements in HER2-positive brain metastases. Cancer Research, 2022, 82, P5-07-04-P5-07-04.	0.4	0
166	Abstract PD4-09: Comprehensive assessment of the genomic landscape of breast cancer brain metastases reveals targetable alterations and genomic signatures relevant to immune-checkpoint and PARP inhibitors. Cancer Research, 2022, 82, PD4-09-PD4-09.	0.4	0